IQVIA Holdings Inc. - IQV STOCK NEWS

IQVIA has announced a strategic collaboration with HealthCore, Inc. to enhance real world evidence (RWE) studies in the U.S. The partnership aims to improve the quality and efficiency of RWE, which integrates data from electronic medical records, pharmacy claims, and patient-reported outcomes. The collaboration will focus on advancing research innovations, including external comparators and pragmatic trials, utilizing HealthCore’s extensive data sources. This initiative is expected to support better healthcare decision-making and patient outcomes, leveraging IQVIA's expansive analytics and technology capabilities.

IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2021 Global Healthcare Conference on September 14, 2021, at 12:15 p.m. EDT. A live audio webcast will be available on their website, with a replay accessible later that day. IQVIA is a global leader in analytics, technology solutions, and clinical research, operating in over 100 countries with approximately 74,000 employees. The company focuses on improving healthcare outcomes and patient privacy.

IQVIA (NYSE:IQV) has enhanced its Medical Information (MI) Contact Center services by integrating AI-powered technologies. This upgrade aims to improve response times and the overall experience for consumers, healthcare professionals (HCPs), and patients globally. The MI services now feature virtual agents working alongside human agents, enabling 24/7 support and efficient management of inquiries and adverse events. With operations in over 170 countries and support in 50 languages, IQVIA's advancements are set to bolster brand loyalty and trust in the life sciences industry.

IQVIA reported strong financial results for Q2 2021, with revenues of $3,438 million, a 36.4% increase year-over-year. Technology & Analytics Solutions revenue was $1,353 million, while Research & Development Solutions grew to $1,891 million, a 53.1% increase. The company's backlog rose to $23.9 billion, with an expected conversion of $6.6 billion into revenue. GAAP net income reached $175 million, compared to a loss last year. IQVIA raised its full-year guidance, estimating revenues of $13,550 - $13,700 million and adjusted diluted EPS of $8.70 - $8.90.

The IQVIA Institute for Human Data Science released a report titled Digital Health Trends 2021, highlighting the growing role of digital health tools in mainstream medicine. In 2020, over 90,000 new health apps emerged, totaling 350,000 available to consumers, with disease management apps rising to 47% of usage. The report emphasizes the increasing effectiveness of these tools, validated wearables, and the substantial body of evidence supporting digital health's inclusion in treatment guidelines. Key developments include expanded commercialization pathways and the incorporation of digital therapeutics and biomarkers in clinical trials.

IQVIA Holdings Inc. (NYSE:IQV) is set to announce its Q2 2021 financial results on July 27, 2021, before market open. A conference call will follow at 9:00 a.m. Eastern Time. Investors can access the earnings release and financial details on their Investor Relations website. Registration for the call is required in advance to obtain connection details. A replay will be available post-event. IQVIA is a leader in analytics and technology solutions for the life sciences, with over 72,000 employees operating in more than 100 countries.

IQVIA has launched the Clinical Data Analytics Suite (CDAS), a SaaS-based platform that integrates clinical trial data, enabling better access and predictive analytics. This solution aims to address the challenges posed by decentralized trials by allowing stakeholders to manage both structured and unstructured data efficiently. CDAS enhances decision-making in trial design and resource allocation, ultimately improving patient safety and accelerating drug development. Core components of CDAS are now available, demonstrating IQVIA's commitment to leveraging AI and machine learning in clinical research.

Q2 Solutions, a subsidiary of IQVIA, has announced a significant expansion at its Alba Campus in Livingston, Scotland. This development includes enhancing laboratory capabilities in areas such as genomics and flow cytometry, supporting growth in biopharma and pharma sectors. The expansion, supported by a multi-million-pound grant from Scottish Enterprise, aims to produce better patient outcomes and creates over 150 new jobs. Key advancements include next-generation genetic sequencing, advanced flow cytometry technologies, and a clean room dedicated to PBMC isolation.

Q2 Solutions, a subsidiary of IQVIA, has partnered with Tasso Inc. to develop diagnostic tests for decentralized clinical trials. Utilizing Tasso's patient-friendly blood collection devices, the collaboration addresses the increased demand for remote clinical trials during the COVID-19 pandemic. A pilot study validated Tasso's method against traditional blood draws, showing effective capillary blood volume retrieval. This partnership aims to enhance patient participation in clinical trials and improve diagnostic testing accessibility.